research: tivozanib, new VEGF inhibitor in clinical trials
Posted Dec 18 2010 12:00am
A drug in Phase I clinical trials is showing good results in treatment for metastatic breast cancer when combined with paclitaxel. AVEO Pharmaceutical Company’s tivozanib is a selective VEGF receptor inhibitor. Dr. Erica L. Mayer, medical oncologist at the Breast … Continue reading →
A drug in Phase I clinical trials is showing good results in treatment for metastatic breast cancer when combined with paclitaxel. AVEO Pharmaceutical Company’s tivozanib is a selective VEGF receptor inhibitor. Dr. Erica L. Mayer, medical oncologist at the Breast … Continue reading →